Comparison

Selnoflast European Partner

Item no. HY-132831-50mg
Manufacturer MedChem Express
CASRN 2260969-36-4
Amount 50 mg
Quantity options 100 mg 10 mM x 1 mL 10 mg 1 ea 25 mg 50 mg 5 mg
Category
Type Chemicals
Specific against other
Purity 99.46
Formula C20H29N3O3S
Citations [1]Vande Walle L, et al. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2023 Nov 29.
[2]Klughammer B, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med. 2023 Nov;13(11):e1471.
[3]McManus RM, et al. NLRP3 inflammasome signalling in Alzheimer's disease[J]. Neuropharmacology. 2024 Jul 1;252:109941.
[4]Teske KA, et al. Interrogating direct NLRP3 engagement and functional inflammasome inhibition using cellular assays[J]. Cell Chem Biol. 2024 Feb 15;31(2):349-360.e6.
[5]Zhang L, et al. Role of NLRP3 inflammasome in central nervous system diseases[J]. Cell Biosci. 2024 Jun 7;14(1):75.
Smiles O=C(NS(=O)(C1CCN(CC1)CC)=O)NC2=C(CCC3)C3=CC4=C2CCC4
ECLASS 10.1 32160000
ECLASS 11.0 32160000
UNSPSC 12000000
Alias Somalix, RO-7486967, IZD334
Shipping condition Cool pack
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
COVID-19-immunoregulation
Manufacturer - Targets
Interleukin Related; NOD-like Receptor (NLR)
Shipping Temperature
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Molecular Weight
391.53
Product Description
Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease[1][2][3][4][5]
Manufacturer - Research Area
Inflammation/Immunology; Neurological Disease
Solubility
1M NaOH : 3.33 mg/mL (adjust pH to 12 with 1M NaOH)|DMSO : 5 mg/mL (ultrasonic; adjust pH to 8 with 1M NaOH)
Manufacturer - Pathway
Immunology/Inflammation
Isoform
NLRP3
Clinical information
No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 50 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close